{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:39:24Z","timestamp":1793165964589,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,26]],"date-time":"2023-02-26T00:00:00Z","timestamp":1677369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011851","name":"Kom op tegen Kanker","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011851","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.bone.2023.116722","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T17:56:57Z","timestamp":1678125417000},"page":"116722","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Risk of medication-related osteonecrosis of the jaw after dental extractions in patients receiving antiresorptive agents \u2014 A retrospective study of 240 patients"],"prefix":"10.1016","volume":"170","author":[{"given":"Ruxandra","family":"Coropciuc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaat","family":"Coopman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melisa","family":"Garip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelien","family":"Gielen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantinus","family":"Politis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Van den Wyngaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Beuselinck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2023.116722_bb0005","doi-asserted-by":"crossref","first-page":"e618","DOI":"10.1016\/j.clbc.2021.04.009","article-title":"Bone-modifying agents (BMAs) in breast cancer","volume":"21","author":"Shapiro","year":"2021","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.bone.2023.116722_bb0010","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.bone.2023.116722_bb0015","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1359\/JBMR.040305","article-title":"A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, postmenopausal women","volume":"19","author":"Bekker","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2023.116722_bb0020","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.bone.2023.116722_bb0025","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases","volume":"62","author":"Ruggiero","year":"2004","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.bone.2023.116722_bb0030","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","article-title":"American Association of Oral and Maxillofacial Surgeons\u2019 position paper on medication-related osteonecrosis of the Jaws\u20142022 update","volume":"80","author":"Ruggiero","year":"2022","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.bone.2023.116722_bb0035","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ctrv.2018.06.007","article-title":"Medication-related osteonecrosis of the jaw: prevention, diagnosis and management in patients with cancer and bone metastases","volume":"69","author":"Otto","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bone.2023.116722_bb0040","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jcms.2010.05.009","article-title":"Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: not just a sporadic coincidence - a multi-Centre study","volume":"39","author":"Otto","year":"2011","journal-title":"J. Cranio-Maxillofac. Surg."},{"key":"10.1016\/j.bone.2023.116722_bb0045","first-page":"925","article-title":"Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review","volume":"29","author":"Ng","year":"2021","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.bone.2023.116722_bb0050","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4103\/2231-0762.178742","article-title":"Medication-related osteonecrosis of the jaw: clinical and practical guidelines","volume":"6","author":"Rosella","year":"2016","journal-title":"J. Int. Soc. Prev. Community Dent."},{"key":"10.1016\/j.bone.2023.116722_bb0055","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.job.2019.03.005","article-title":"Medication-related osteonecrosis of the jaw: a literature review","volume":"61","author":"Kuroshima","year":"2019","journal-title":"J. Oral Biosci."},{"key":"10.1016\/j.bone.2023.116722_bb0060","first-page":"447","article-title":"Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer","volume":"24","author":"Stopeck","year":"2016","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.bone.2023.116722_bb0065","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bone.2023.116722_bb0070","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/annonc\/mdn526","article-title":"Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan","volume":"20","author":"Ripamonti","year":"2009","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bone.2023.116722_bb0075","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.oooo.2018.09.008","article-title":"Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment","volume":"127","author":"Nicolatou-Galitis","year":"2019","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"10.1016\/j.bone.2023.116722_bb0080","first-page":"869","article-title":"Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors","volume":"26","author":"van Cann","year":"2018","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.bone.2023.116722_bb0085","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bone.2023.116722_bb0090","first-page":"3483","article-title":"Prospective observational study of treatment pattern, effectiveness and safety of zoledronic acid therapy beyond 24 months in patients with multiple myeloma or bone metastases from solid tumors","volume":"21","author":"van den Wyngaert","year":"2013","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.bone.2023.116722_bb0095","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s00198-013-2575-3","article-title":"Risk of osteonecrosis in patients taking bisphosphonates for prevention of osteoporosis: a systematic review and meta-analysis","volume":"25","author":"Lee","year":"2014","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2023.116722_bb0100","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/odi.12447","article-title":"Medication-related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis","volume":"22","author":"Bagan","year":"2016","journal-title":"Oral Dis."},{"key":"10.1016\/j.bone.2023.116722_bb0105","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.jcms.2018.05.003","article-title":"Conservative surgical treatment of medication related osteonecrosis of the jaw (MRONJ) lesions in patients affected by osteoporosis exposed to oral bisphosphonates: 24 months follow-up","volume":"46","author":"Nisi","year":"2018","journal-title":"J. Cranio-Maxillofac. Surg."},{"key":"10.1016\/j.bone.2023.116722_bb0110","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bone.2023.116722_bb0115","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a Task Force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2023.116722_bb0120","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1056\/NEJMp068157","article-title":"Osteonecrosis of the jaw \u2014 do bisphosphonates pose a Risk?","volume":"355","author":"Bilezikian","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2023.116722_bb0125","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jcms.2015.03.039","article-title":"Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: a trigger for BRONJ development?","volume":"43","author":"Otto","year":"2015","journal-title":"J. Cranio-Maxillofac. Surg."},{"key":"10.1016\/j.bone.2023.116722_bb0130","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1007\/s00784-016-2004-z","article-title":"Platelet-rich fibrin may reduce the risk of delayed recovery in tooth-extracted patients undergoing oral bisphosphonate therapy: a trial study","volume":"21","author":"Asaka","year":"2017","journal-title":"Clin. Oral Investig."},{"key":"10.1016\/j.bone.2023.116722_bb0135","doi-asserted-by":"crossref","first-page":"e771","DOI":"10.4317\/jced.56837","article-title":"Prevention of medication related osteonecrosis of the jaw after dentoalveolar surgery: an institution\u2019s experience","volume":"12","author":"\u015eahin","year":"2020","journal-title":"J Clin Exp Dent"},{"key":"10.1016\/j.bone.2023.116722_bb0140","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.joms.2017.06.004","article-title":"Use of leukocyte- and platelet-rich fibrin in the treatment of medication-related osteonecrosis of the jaws","volume":"76","author":"Maluf","year":"2018","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.bone.2023.116722_bb0145","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.joms.2010.06.200","article-title":"Relevance of a prolonged preoperative antibiotic regime in the treatment of bisphosphonate-related osteonecrosis of the jaw","volume":"69","author":"Hoefert","year":"2011","journal-title":"J. Oral Maxillofac. Surg."},{"issue":"5","key":"10.1016\/j.bone.2023.116722_bb0150","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/odi.13294","article-title":"Alveolar bone histological necrosis observed prior to extractions in patients, who received bone-targeting agents","volume":"26","author":"Nicolatou-Galitis","year":"2020","journal-title":"Oral Dis."},{"key":"10.1016\/j.bone.2023.116722_bb0155","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1080\/17843286.2017.1348001","article-title":"Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab","volume":"73","author":"Loyson","year":"2018","journal-title":"Acta Clin. Belg."},{"key":"10.1016\/j.bone.2023.116722_bb0160","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.jcms.2020.02.006","volume":"48","author":"Poxleitner","year":"2020","journal-title":"J. Cranio-Maxillofac. Surg."},{"key":"10.1016\/j.bone.2023.116722_bb0165","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.bjoms.2017.06.014","article-title":"Medication-related osteonecrosis of the jaw in oncological patients with skeletal metastases: conservative treatment is effective up to stage 2","volume":"55","author":"Coropciuc","year":"2017","journal-title":"Br. J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.bone.2023.116722_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115676","article-title":"Adjuvant therapies for MRONJ: a systematic review","volume":"141","author":"Govaerts","year":"2020","journal-title":"Bone"},{"key":"10.1016\/j.bone.2023.116722_bb0175","series-title":"Analysing Survival Data from Clinical Trials and Observational Studies","author":"Marubini","year":"2004"},{"key":"10.1016\/j.bone.2023.116722_bb0180","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.bone.2023.116722_bb0185","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s00198-012-2239-8","article-title":"Tooth extraction in osteoporotic patients taking oral bisphosphonates","volume":"24","author":"Mozzati","year":"2013","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2023.116722_bb0190","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/jcpe.12455","article-title":"Occurrence and risk indicators of medication-related osteonecrosis of the jaw after dental extraction: a systematic review and meta-analysis","volume":"42","author":"Gaudin","year":"2015","journal-title":"J. Clin. Periodontol."},{"key":"10.1016\/j.bone.2023.116722_bb0195","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40264-017-0582-6","article-title":"Treatment of medication-related osteonecrosis of the jaw and its impact on a patient\u2019s quality of life: a single-center, 10-year experience from Southern Italy","volume":"41","author":"Oteri","year":"2018","journal-title":"Drug Saf."},{"key":"10.1016\/j.bone.2023.116722_bb0200","article-title":"Interventions for managing medication-related osteonecrosis of the jaw","volume":"2022","author":"Beth-Tasdogan","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.bone.2023.116722_bb0205","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.joms.2009.10.026","article-title":"Occurrence of bisphosphonate-related osteonecrosis of the jaw after surgical tooth extraction","volume":"68","author":"Saia","year":"2010","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.bone.2023.116722_bb0210","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1002\/jbmr.1669","article-title":"Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis","volume":"27","author":"Aguirre","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2023.116722_bb0215","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1080\/10428190802483778","article-title":"Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates","volume":"49","author":"Montefusco","year":"2008","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.bone.2023.116722_bb0220","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdn554","article-title":"Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid","volume":"20","author":"Dimopoulos","year":"2009","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bone.2023.116722_bb0225","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2334\/josnusd.21-0016","article-title":"Lack of evidence in reducing risk of mronj after teeth extractions with systemic antibiotics","volume":"63","author":"Cabras","year":"2021","journal-title":"J. Oral Sci."},{"key":"10.1016\/j.bone.2023.116722_bb0230","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.clinthera.2007.08.008","article-title":"A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with Oral bisphosphonates: prevalence, risk factors, and clinical characteristics","volume":"29","author":"Pazianas","year":"2007","journal-title":"Clin. Ther."},{"key":"10.1016\/j.bone.2023.116722_bb0235","doi-asserted-by":"crossref","DOI":"10.4317\/jced.54154","article-title":"The role of leucocyte-rich and platelet-rich fibrin (L-PRF) in the treatment of the medication-related osteonecrosis of the jaws (MRONJ)","author":"Cano-Duran","year":"2017","journal-title":"J Clin Exp Dent"},{"key":"10.1016\/j.bone.2023.116722_bb0240","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/j.joms.2007.08.003","article-title":"Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment","volume":"65","author":"Marx","year":"2007","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.bone.2023.116722_bb0245","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1007\/s00198-017-4063-7","article-title":"A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ?","volume":"28","author":"Hasegawa","year":"2017","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2023.116722_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2020.e03795","article-title":"Efficacy of a high-dose antiresorptive drug holiday to reduce the risk of medication-related osteonecrosis of the jaw (MRONJ): a systematic review","volume":"6","author":"Ottesen","year":"2020","journal-title":"Heliyon"},{"key":"10.1016\/j.bone.2023.116722_bb0255","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/jbmr.4705","article-title":"Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post hoc analyses","volume":"37","author":"Cosman","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2023.116722_bb0260","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"Miller","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.bone.2023.116722_bb0265","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J. Bone Miner. Res."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328223000558?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328223000558?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:46:32Z","timestamp":1762659992000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328223000558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":53,"alternative-id":["S8756328223000558"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2023.116722","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of medication-related osteonecrosis of the jaw after dental extractions in patients receiving antiresorptive agents \u2014 A retrospective study of 240 patients","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2023.116722","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116722"}}